Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Disease
- Diagnostic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 222534
The Licensed Product means any product comprising, incorporating or containing any Compound, or an alternate form of any Compound, including, but not limited to, a pharmaceutically acceptable salt, polymorph, crystal form, prodrug, or solvate of any Compound to the extent such alternate form is claimed in the Licensor Patent Rights.
Rolapitant, a Phase III-ready, oncology supportive-care product candidate, is a potent and selective neurokinin-1 (NK-1) receptor antagonist with an extended plasma half-life that has the potential to improve the management of nausea and vomiting experienced by cancer patients undergoing treatment with emetogenic chemotherapy. Phase II clinical testing of rolapitant for the prevention of nausea and vomiting in cancer patients treated with highly emetogenic chemotherapy demonstrated promising five-day activity following the administration of a single dose.
IPSCIO Record ID: 243661
Licensor grants the right to use the Clinical Information and Data generated by or on behalf of Licensor and its Affiliates for the purpose of obtaining Regulatory Approval of the Licensed Product in the Territory.
Licensed Product shall mean a formulation of the Active Ingredient with the Biochronomer formulation, including the formulation designated by APP as APF530.
Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and Radiotherapy.
The Field shall mean any and all human applications.
APF530 is currently in Phase 3 trials in the U.S. for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
IPSCIO Record ID: 243475
Project means Hedgehog Project and/or Hsp90 Project.
Hsp90 Diagnostic means a product or service for determining a person that is susceptible to treatment with a Hsp90 Therapeutic and/or monitoring such treatment and/or providing a prognosis of such treatment, in each case such treatment being for the purpose of treating and/or preventing a disease, disorder or condition.
Hsp90 Therapeutic means one or more molecules that primarily (i.e. the most potent activity) target and modulate one or more of Heat Shock Protein 90 (Hsp90) [and/or cochaperones of Heat Shock Protein 90 ( e.g. Hip and Hop), but not client proteins of Heat Shock Protein 90 such as c-Kit and EGFR,] and compositions that contain such a molecule(s). For the avoidance of doubt, the chemical entities disclosed and/or claimed in the Patent Rights indicated in Exhibit Y and IPI 504 are included as Hsp90 Therapeutics.
Hedgehog Diagnostic means a product or service for determining a person that is susceptible to treatment with a Hedgehog Therapeutic and/or monitoring such treatment and/or providing a prognosis of such treatment, in each case such treatment being for the purpose of treating and/or preventing a disease, disorder or condition.
Hedgehog Therapeutic means one or more molecules that primarily target (i.e. the most potent activity) and modulate one or more member(s) of the Hedgehog pathway and compositions that contain such a molecule(s). For the avoidance of doubt, the chemical entities disclosed and/or claimed in the Patent Rights [, and IPI 609, the IPI 609 polymorph, and reduced A-ring analogs of IPI 609] are included as Hedgehog Therapeutics.
The Licensor Patents are for Analogs ofBenzoquinone-Containing Ansamycins and Methods of Use Thereof, and, Ansamycin Formulations and Methods of use Thereof, and, Methods of Treatment Using Hydroquinone Ansamycins, and, Crystal Form, and, Cyclopamine Analogs and Methods of Use Thereof , and, Dosing Regimens for the Treatment of Cancer, and, Methods for Synthesizing Cyclopamine Analogs.
“Indication†means a type of cancer (tumor type) or a disease, disorder or a condition other than a type of cancer.
IPSCIO Record ID: 249348
Hsp90 Diagnostic means a product or service for determining a person that is susceptible to treatment with a Hsp90 Therapeutic and/or monitoring such treatment and/or providing a prognosis of such treatment, in each case such treatment being for the purpose of treating and/or preventing a disease, disorder or condition.
Hsp90 Therapeutic means one or more molecules that primarily (i.e. the most potent activity) target and modulate one or more of Heat Shock Protein 90 (Hsp90) [and/or cochaperones of Heat Shock Protein 90 ( e.g. Hip and Hop), but not client proteins of Heat Shock Protein 90 such as c-Kit and EGFR,] and compositions that contain such a molecule(s). For the avoidance of doubt, the chemical entities disclosed and/or claimed in the Patent Rights indicated in Exhibit Y and IPI 504 are included as Hsp90 Therapeutics.
Hedgehog Diagnostic means a product or service for determining a person that is susceptible to treatment with a Hedgehog Therapeutic and/or monitoring such treatment and/or providing a prognosis of such treatment, in each case such treatment being for the purpose of treating and/or preventing a disease, disorder or condition.
Hedgehog Therapeutic means one or more molecules that primarily target (i.e. the most potent activity) and modulate one or more member(s) of the Hedgehog pathway and compositions that contain such a molecule(s). For the avoidance of doubt, the chemical entities disclosed and/or claimed in the Patent Rights [, and IPI 609, the IPI 609 polymorph, and reduced A-ring analogs of IPI 609] are included as Hedgehog Therapeutics.
The Licensee Patents are for Analogs ofBenzoquinone-Containing Ansamycins and Methods of Use Thereof, and, Ansamycin Formulations and Methods of use Thereof, and, Methods of Treatment Using Hydroquinone Ansamycins, and, Crystal Form, and, Cyclopamine Analogs and Methods of Use Thereof , and, Dosing Regimens for the Treatment of Cancer, and, Methods for Synthesizing Cyclopamine Analogs.
IPSCIO Record ID: 381105
TAK-385 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-385 Licensed Compound.
TAK-448 Licensed Product means any pharmaceutical product, including all forms, presentations, strengths, doses, and formulations (including any method of delivery) containing a TAK-448 Licensed Compound.
Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.
TAK-385 Licensed Compound means (a) the chemical compound coded by Licensee as TAK-385 and the structure of which is set forth in Agreement (TAK-385 Licensed Compound); (b) any compound other than TAK-385 that is Covered by any Licensee Patent Right set forth in Agreement (Licensee Patent Rights) that also Covers TAK-385; and (c) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).
TAK-448 Licensed Compound means (a) the oligopeptide coded by Licensee as TAK-448 and the structure of which is set forth in Agreement (TAK-448 Licensed Compound); (c) any oligopeptide other than TAK-448 that is Covered by any Licensee Patent Right set forth in Agreement (Licensee Patent Rights) that also Covers TAK-448; and (d) any radioisomers, racemates, solvates, salt forms, bases, anhydrides, hydrates, polymorphs, ester forms or prodrugs of any compound described in clause (a).
Licensee Patent Rights means (a) those Patent Rights set forth in Agreement part (a) (TAK-385 Patent Rights), (b) those Patent Rights set forth in Agreement part (b) (TAK-448 Patent Rights), and (c) all Patent Rights (other than Licensor Patent Rights and Joint Patent Rights) Controlled by Licensee during the Term that Cover any Invention made by or on behalf of Licensee after the Effective Date that Covers a Licensed Compound or any Licensed Product or is otherwise necessary to Exploit any Licensed Compound or Licensed Product.
Men’s Health Field means the treatment, prevention, cure, or control of symptoms associated with prostate cancer.
Women’s Health Field means the treatment, prevention, cure, or control of symptoms associated with Uterine Fibroids or Endometriosis.
Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign smooth muscle tumors of the uterus.
Endometriosis is a disease of the female reproductive system in which cells similar to those in the endometrium, the layer of tissue that normally covers the inside of the uterus, grow outside the uterus.
relugolix (TAK-385) is a phase 3 drug candidate that has been evaluated in over 1,300 patients to date. Relugolix has successfully demonstrated significant clinical benefit and was generally well-tolerated across multiple, large, randomized phase 2 clinical trials in three different indications. Relugolix is being developed as an oral, once-daily, potential best-in-class gonadotropin-releasing hormone (GnRH) receptor antagonist for uterine fibroids, endometriosis and prostate cancer.
IPSCIO Record ID: 263955
Cancer Field means the prophylactic or therapeutic administration to humans or non-human animals as an agent, either alone or in combination with other agents, for the prevention, treatment or palliation of cancer including neoadjuvant, adjuvant or supportive care and/or as part of combination with radiotherapy, surgery, chemo-, biologic- or other therapy associated with cancer, including, but not limited to, pain and bone/skeletal complications or indications from bone metastasis.
